|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Rituxan Sensitivity (CD20)
Test Code10981
CPT Codes
86356
Preferred Specimen
5 mL whole blood or bone marrow collected in a sodium heparin (green-top) tube or EDTA (lavender-top) tube or ACD solution B (yellow-top) tube
Minimum Volume
1 mL
Other Acceptable Specimens
5 mL buffy coat or fresh (unfixed) tissue • CSF or tissue biopsy or fluid or pleural fluid
Transport Container
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 72 hours
Refrigerated: Unacceptable
Frozen: Unacceptable
Refrigerated: Unacceptable
Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Clotted or fixed sample
Methodology
Flow Cytometry (FC)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Daily; Report available: 2-3 days
Reference Range
See Laboratory Report
Clinical Significance
CD20 antigen is expressed on the surface of >90% of B-cell Non-Hodgkin's Lymphomas (NHL). Binding to CD20 antigen is necessary for the antitumor effect of Rituxan®.